Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Large Drop in Short Interest

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 51,700 shares, a drop of 12.5% from the February 28th total of 59,100 shares. Based on an average daily trading volume, of 16,800 shares, the days-to-cover ratio is currently 3.1 days. Currently, 3.8% of the company’s shares are short sold.

Alaunos Therapeutics Price Performance

Alaunos Therapeutics stock opened at $2.80 on Thursday. Alaunos Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $18.50. The firm’s 50 day simple moving average is $1.62 and its 200-day simple moving average is $2.03.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.